Labbate, Craig
Hatogai, Ken
Werntz, Ryan
Stadler, Walter M.
Steinberg, Gary D.
Eggener, Scott
Sweis, Randy F.
Funding for this research was provided by:
National Cancer Institute (K08 CA234392)
Article History
Received: 15 January 2019
Accepted: 22 February 2019
First Online: 11 March 2019
Ethics approval and consent to participate
: The patient provided full consent for participation and publication. Ethics approval for a case report is deemed exempt by the University of Chicago IRB.
: Available upon request.
: RFS reports consulting and honoraria from Eisai, BMS, AstraZeneca, Puma, Exelixis, and research support from Bayer, BMS, and Eisai. WMS reports consulting and honoraria from Astra-Zeneca, Bayer, BMS, Caremark/CVS, Eisai, Genentech, and Pfizer and research support from Abbvie, Astra-Zeneca, Astellas (Medivation), Bayer, Bristol-Myers-Squibb, Boehringer-Ingelheim, Calithera, Eisai, Exilixis, Genentech (Roche), Johnson & Johnson (Janssen), Merck, Novartis, Pfizer, Seattle Genetics, Tesaro, X4Pharmaceuticals. GDS is scientific advisor and/or investigator for Merck, BMS, AstraZeneca, Roche, Janssen, Ferring, Boston Scientific, Natera, QED Therapeutics, FKD, Fidia, PhotoCure, ColdGenesys, Urogen, Epivax Oncology, Altor Bioscience, BioCancell, Taris Biomedical. CL, KH, RW, and SE declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.